Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
The purpose of this phase II trial is to evaluate the safety and efficacy of the addition of pembrolizumab to olaparib in patients with metastatic pancreatic cancer with germline BRCA 1or BRCA 2 mutations.
Study ID: NCI-2020-06838
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Olaparib, Pembrolizumab